louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02083523: Project CHOICE: Efficacy Testing of CHOICE and CHOICE+Normative Feedback Interventions
Official title: PROJECT CHOICE: Efficacy Testing of Motivational Interviewing (MI) for Adolescents Referred for Substance Use Concerns
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Substance-related Disorders
Keywords: Motivational Interview, normative feedback, adolescents
Lead sponsor: University of Illinois at Urbana-Champaign
Sponsor class: OTHER
First posted: 2014-03-11
Enrollment: 48
Sex: ALL
Minimum age (years): 13
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will use a pilot test format to examine the efficacy of a brief Motivational Interviewing (MI) intervention developed by the investigator Dr. Douglas Smith called CHOICE (Compassionate Helpers Openly Inviting Client Empowerment)with youth referred for substance abuse assessments to substance abuse treatment agencies in Chicago and Urbana, IL.

Detailed description: This study will use a pilot test format to examine the efficacy of a brief Motivational Interviewing (MI) intervention developed by the investigator Dr. Douglas Smith called CHOICE (Compassionate Helpers Openly Inviting Client Empowerment)with youth referred for substance abuse assessments to substance abuse treatment agencies in Chicago and Urbana, IL. The study will have two arms: one group will receive the standard CHOICE Motivational Interview (MI) while the second group will receive the CHOICE Motivational Interview with a Normative Feedback component, called CHOICE+ (CHOICE Plus). The hypothesis is that there will be no difference in outcomes between those that receive the standard CHOICE and those that receive the CHOICE+ MI.

Eligibility criteria: Inclusion Criteria:

* Youth 13-19 years of age (and their parents or legal guardians if their youth has been referred for an assessment with the Prairie Center counseling staff.)
* referred for an assessment to see if they need substance use disorder treatment
* have used substances on 13 or more days out of the past 90 days or scored higher than 2 on the CRAFT assessment. -

Exclusion Criteria:

* Low cognitive functioning

Primary outcomes:
measure: % Readiness to Change
timeFrame: Day One
Secondary outcomes:
measure: Days of Substance Use Treatment
timeFrame: 3 months post intake
Other outcomes:
measure: Substance Use Frequency
timeFrame: 3 months post intake
Locations:
Study officials:
affiliation: University of Illinois Urbana Champaign
name: Douglas Smith, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00562250: Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
Official title: Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2007-11-22
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers. In addition, the safety and tolerability of dapagliflozin with be assessed alone and while taking glimepiride


Eligibility criteria: Inclusion Criteria:

* Healthy subjects with BMI of 18-32 kg/m2

Exclusion Criteria:

* Abnormal physical or lab findings
* Allergies to any sulfonylurea or related compounds

Primary outcomes:
measure: Maximum plasma concentration and exposure to glimepiride and dapagliflozin when administered alone and administered together
timeFrame: plasma concentrations will be measures as specified timepoints for 72 hours after each administred dose
Secondary outcomes:
measure: Measures of the plasma concentration of the active metabolite of glimepiride when administered alone or coadministered with glimepiride
timeFrame: for 72 hours after each administered dose
measure: Recorded adverse events
timeFrame: for 72 hours after each administered dose
Other outcomes:
Locations:
city: Vicente Lopez
country: Argentina
facility: Local Institution
state: Buenos Aires
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT07006350: Heart Failure and Therapeutic Education
Official title: Heart Failure and Therapeutic Education
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Health Education
Diet, Sodium-Restricted
Disease Management
Therapeutics
Lead sponsor: Centre Hospitalier de Gonesse
Sponsor class: OTHER
First posted: 2025-06-05
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be selected from adult patients diagnosed with heart failure who received care at the Heart Failure Therapeutic Education Unit (UTIC) of the General Hospital (CHG). The population includes patients who were followed by the UTIC during the years 2023 and 2024. Only those who meet the inclusion criteria and do not fall under the exclusion criteria (e.g., minors, non-UTIC patients, or those who oppose the use of their data) will be considered for the study.

Brief summary: This study looks at whether a special program called the Heart Failure Therapeutic Education Unit (UTIC) helps reduce hospital stays for people with heart failure. It is a retrospective study, which means we are looking back at the records of patients who were followed at the UTIC in 2023 and 2024.

We want to find out two things:

If patients who followed the UTIC program were hospitalized less often.

If the advice they received-especially about diet-helped improve their condition.

Only adult patients who were treated at the UTIC are included in the study. We will not use data from patients who are under 18, were not treated in UTIC, or did not give permission to use their information.

The study takes place over two weeks, from March 24 to April 6, 2025.


Eligibility criteria: Inclusion Criteria:

* Adults (age ≥ 18 years)
* Patients diagnosed with heart failure
* Patients followed in the Heart Failure Therapeutic Education Unit (UTIC) at the General Hospital (CHG)
* Follow-up occurred during the years 2023 or 2024

Exclusion Criteria:

* Patients who do not consent to the use of their medical data
* Minors (under 18 years old)
* Patients not followed in the UTIC program

Primary outcomes:
measure: Number of hospitalizations among patients with heart failure who were followed at the Unité Thérapeutique de l'Insuffisance Cardiaque (UTIC).
timeFrame: Review of hospital records for patients seen in 2023-2024.
Secondary outcomes:
Other outcomes:
Locations:
city: Gonesse
country: France
facility: France
Study officials:
References:
Clinical trial NCT05630950: LDCT-SC-FI Low-dose CT Screening for Lung Cancer
Official title: Low-dose CT Screening for Lung Cancer Combined to Different Smoking Cessation Methods in Finland
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Lung Cancer Screening
Lead sponsor: Oulu University Hospital
Sponsor class: OTHER
First posted: 2022-11-30
Enrollment: 200
Sex: ALL
Minimum age (years): 50
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized phase II trial investigating different smoking cessation methods in study subjects undergoing lung cancer screening with low-dose CT (LDCT). The study also evaluates feasibility and outcomes of LDCT screening and potential biomarkers and AI-based evaluation on CT-scans. The study subjects fulfilling I/E-criteria are randomized in 1:1 fashion to yearly LDCT for two rounds with standard smoking cessation (control) or same LDCT approach combined to mobile application based smoking cessation (intervention).


Eligibility criteria: Inclusion Criteria:

* Able to provide written informed consent
* Age between 50-74
* Smoked ≥ 15 cigarettes/day for ≥ 25 years or smoked ≥ 10 cigarettes/day for ≥ 30 years and are active smokers (smoking during the last two weeks)
* Access to a smartphone (iPhone or Android)

Exclusion Criteria:

* A moderate or bad self-reported health; e.g. unable to climb two flights of stairs
* Body weight ≥ 140 kilogram
* Current or past melanoma, lung, renal or breast cancer
* A chest CT examination less than one year before inclusion
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
* Subject is unwilling or unable to comply with treatment and trial instructions
* Any condition that study investigators consider an impediment to safe trial participation

Primary outcomes:
measure: Number of active smokers at 3 months
timeFrame: 3 months
Secondary outcomes:
measure: Number of subjects who have reduced the amount of smoked cigrattes/d at 3 months
timeFrame: 3 months
measure: Number of subjects who have reduced the amount of smoked cigrattes/d at 6 months
timeFrame: 6 months
measure: The reduction in number of smoked cigarettes/d at 3 months
timeFrame: 3 months
measure: The reduction in number of smoked cigarettes/d at 6 months
timeFrame: 6 months
measure: The percentage of reduction in number of smoked cigarettes/d at 3 months
timeFrame: 3 months
measure: The percentage of reduction in number of smoked cigarettes/d at 6 months
timeFrame: 6 months
measure: Sensitivity of CT screening in the whole cohort
timeFrame: At 2 years
measure: Costs related to CT screening including additional investigations
timeFrame: At 2 years
Other outcomes:
Locations:
city: Oulu
country: Finland
facility: Oulu University Hospital
city: Vaasa
country: Finland
facility: Vaasa Central Hospital
Study officials:
References:
Clinical trial NCT06941350: A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Official title: A Phase I/II Clinical Study Evaluating the Safety and Efficacy of NCR102 Injection in the Treatment of Acute Graft-versus-Host Disease (aGVHD)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Acute Graft-versus-Host Disease
Keywords: SR-aGVHD
NCR102
second-line treatment failure
Lead sponsor: Nuwacell Biotechnologies Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-04-23
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Detailed description: An open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability and preliminary efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Eligibility criteria: Inclusion Criteria:

* Age\>18 years and \<70 years old (including threshold), gender not limited；
* Grade II to IV gastrointestinal involvement acute graft-versus-host disease(aGVHD)；
* Subjects with Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)；
* Failed to second-line aGVHD treatment;
* Subjects will receive NCR102 injection treatment within 3 days after enrollment;
* Voluntarily sign an informed consent form.

Exclusion Criteria:

* Subjects have lung disease, and investigators have determined that they are not suitable for the study;
* Subjects with severe hepatic vein occlusion disease or sinus vein occlusion syndrome;
* Subjects with signs/symptoms of chronic GVHD;
* Subjects who are clinically assessed by the investigator could not be ruled out as having diarrhea caused by cytomegalovirus (CMV) enteritis, transplant related thrombotic microvascular disease (TA-TMA), or digestive tract infection;
* Eastern Cooperative Oncology Group(ECOG)\>3；
* Subjects have other diseases or physiological conditions that may interfere with the evaluation results of this trial, or life-threatening complications；
* Subjects had active malignant solid tumors within the past 5 years；
* Subjects had a known history of severe allergies to blood products, or heterologous proteins.

Primary outcomes:
measure: Adverse Event(AE) or Serious Adverse Event(SAE)
timeFrame: 100 days after first administration of NCR102 injection
Secondary outcomes:
measure: ORR at Day 28
timeFrame: 28 days after first dose administration
measure: CRR at Day 28
timeFrame: 28 days after first dose administration
measure: ORR at Day 56
timeFrame: 56 days after first dose administration
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03401450: Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block
Official title: Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: ACL Surgery
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2018-01-17
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, randomized, single blinded trial involving human subjects. The goal of this study is to determine an optimal location (proximal or distal) for the nerve block and whether it will make a difference in how much opioid the patient will receive during and after surgery. Ultrasound will identify the adductor canal and the proximal end of the adductor canal/apex of the femoral triangle to determine the location of the blocks.

Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB proximal to true AC with bupivacaine 0.5% 20cc


Eligibility criteria: Inclusion Criteria:

* Patients undergoing unilateral, ACL surgery with allograft.
* Patients who consent to be randomized.
* Patients must be English proficient.

Exclusion Criteria:

* Patients younger than 18 or older than 75 years of age;
* Patients with a history of chronic pain or who are taking medications intended to treat chronic pain such as strong opioids;
* Patients with history of neurologic disorder that can interfere with pain sensation;
* Patients with a history of drug or alcohol abuse;
* Patients who are unable to understand or follow instructions;
* Patients with an allergy or a contraindication to any of the medications used in the study, or patients with a contraindication to any of the study procedures;
* Patients with severe liver disease, renal insufficiency, congestive heart failure, and/ or significant heart disease;
* Patients with a BMI over 42;
* Any patient that the investigators feel cannot comply with all study related procedures.
* Patients who do not tolerate Percocet.

Primary outcomes:
measure: Total Opioid Consumption Intraop Measured by Amounts of Morphine Equivalents
timeFrame: 24 Hours
measure: Total Opioid Consumption Postop Measured by Amounts of Morphine Equivalents
timeFrame: 24 Hours
measure: Side Effects Such as Nausea, Itching, Constipation.
timeFrame: 24 hours
Secondary outcomes:
measure: Motor Block (Muscle Weakness): in PACU and Measured in Surgeons' Clinic at 3, 6 and 12 Months.
timeFrame: 12 months
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Prianka Desai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05529550: Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Official title: Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children With Thalassemia Major
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thalassemia
Keywords: Insulin-like growth factor 1
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2022-09-07
Enrollment: 102
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 67 Children in the age group of 2-18 years with confirmed diagnosis of Beta thalassemia, and 35 healthy control

Brief summary: Many studies done on children with thalassemia have shown a variable prevalence of defective IGF-I concentrations have been shown to be low in the majority of children, with or without GH deficiency. The Aim of this study to assess nutritional status and role of Insulin-like growth factor 1 (IGF-1) and its associating factors in children with thalassemia major


Eligibility criteria: Inclusion Criteria:

* Children in the age group of 2-18 years with confirmed diagnosis of Beta thalassemia major.

Exclusion Criteria:

* Children with other chronic diseases (cardiac, renal, vascular)
* Children with malignancy

Primary outcomes:
measure: IGF-1
timeFrame: at the time of recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Samar Abd El-Hameed
Study officials:
References:
Clinical trial NCT05637892: A Cohort Study of Hydatidiform Mole
Official title: A Multi-center Cohort Study of Hydatidiform Mole
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hydatidiform Mole
Lead sponsor: Women's Hospital School Of Medicine Zhejiang University
Sponsor class: OTHER
First posted: 2022-12-06
Enrollment: 800
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatient or inpatient patients in women's hospital school medicine of zhejiang university and other cooperative hospitals (including tongji hosptial, tongji medical college of hust, qilu hosptial of shandong university, Sun Yat-sen university cancer center) were inclued in this cohort study if the patients met the eligibility requirements and agreed to participate in this study

Brief summary: The purpose of this study is to construct a cohort for the hydatidiform mole.

Detailed description: After being informed about the study and potential risks, all patients who meet the eligibility requirements will be enrolled.

Eligibility criteria: Inclusion Criteria:

1. Patients who are diagnosed with hydatidiform mole (including: complete hydatidiform mole/partial hydatidiform mole; one of twins with hydatidiform mole; ectopic pregnancy hydatidiform mole; macroscopic or microscopic hydatidiform changes indicating early complete or partial hydatidiform mole can not be excluded; atypical placental site nodule) for the first time;
2. Age 13-55 years old;
3. Obtain informed consent and sign an informed consent form

Exclusion Criteria:

1. Patients who are unable to cooperate with the investigation such as mental disorders or cognitive impairment
2. No histopathology diagnosis;
3. Patients with other malignancies

Primary outcomes:
measure: Malignant trophoblastic tumor
timeFrame: 4.5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Women's Hospital School Of Medicine Zhejiang University
name: Weiguo Lv, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04668092: Functional DN for Shortened HS Muscle
Official title: Immediate Effects of Functional Dry Needling on the Length of Shortened Hamstring Muscle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hamstring Contractures
Keywords: Dry needling
LEFS
90-90 SLR
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2020-12-16
Enrollment: 27
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to find whether functional dry needle is helpful to increase the length of shortened hamstring muscle or not

Detailed description: Single pretest-post clinical trial to find immediate effects of functional dry needling to increase the length of the shortened hamstring. This study will be carried on single group which will include male subjects only. The data will be recorded before and immediately after the treatment. A monofilament stainless steel needle will be inserted on three points on hamstring muscle which will include semitendinosus, semimembranosus and bicep femoris. Treatment session will consist of 1 minute 20 seconds for each point on the hamstring and the manipulation will be performed by "Pistoning technique" in which the needle will be drawn out (not fully out of skin) after inserted and then again pushed in and data will be recorded after the treatment session on the basis of increase in length of hamstring which will be measure through 90-90 SLR (AKE) and on the lower extremity functional scale (LEFS)

Eligibility criteria: Inclusion Criteria:

* Having hamstring length less than 80 degree during 90-90 SLR on goniometer,
* also the subject that suffers from knee Osteoarthritis,
* Spondylosis,
* LBP,
* Lumber radiculopathy,
* Subjects with MTrPs and those with hyper lordosis were recruited in the study

Exclusion Criteria:

* subjects suffering from blood clotting disorders such as hemophilia,
* those with deformities such as leg length discrepancy,
* compromised immune system,
* vascular diseases,
* Diabetes,
* People with congenital or metabolic bone disease such as Spondyloepiphyseal Dysplasia and Pregnancy were excluded from the study

Primary outcomes:
measure: 90-90 Straight Leg Raise (SLR)
timeFrame: 1 day
Secondary outcomes:
measure: Lower extremity Functional scale (LEFS)
timeFrame: 1 day
Other outcomes:
Locations:
city: Swat
country: Pakistan
facility: Saidu group of teaching hospital said sharif swat
state: Kpk
Study officials:
affiliation: Riphah International University
name: Muhammad Affan Iqbal, Phd*
role: PRINCIPAL_INVESTIGATOR
References: